CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 108 enrolled
Drug / intervention
Etrasimod +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04682639
NCT04682639Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis

Pfizer·interventional·Posted Dec 24, 2020·Updated May 6, 2024

In Brief

A Phase 2 clinical trial evaluating Etrasimod and Placebo for Eosinophilic Esophagitis. Completed, enrolled 108 participants across 256 sites in 8 countries.

Detailed Summary

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesAustralia, Belgium, Canada, Germany, Netherlands, Spain, Switzerland, United States
CollaboratorsArena is a wholly owned subsidiary of Pfizer

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 24, 2020
Enrollment StartDec 15, 2020
Primary CompletionSep 30, 2022
Study CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.5 years ago

Interventions

Etrasimoddrug

Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.

Placebodrug

Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.

Etrasimoddrug

Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.